The major objective of Dr. Daniela Thorwarth, head of Biomedicical Physics in the Department of Radiooncology at Tübingen University Hospital, is to improve cancer patients’ chances of a cure by applying high-precision individualised radiotherapy. The scientist was awarded an ERC Starting Grant, a highly prestigious grant from the European Research Council that supports up-and-coming research leaders. Thorwarth will use the grant to improve the treatment of tumours without increasing side effects.
ERC Starting Grants are provided for a period of five years to up-and-coming European researchers with a scientific track record that shows great promise. Funding per grant amounts to up to 1.54 million euros and is provided to up-and-coming researchers for particularly innovative ideas. The EU explicitly pursues the principle of “high risk – high gain” and therefore funds projects with an innovative potential that might lead to a paradigm change in their respective field of research.
Dr. Daniela Thorwarth, a physicist who specialises in medical physics and has been head of Biomedical Physics at the University Hospital of Tübingen since 2012, has been awarded an ERC Starting Grant for her project entitled “bio-iRT: biologically individualised model-based radiotherapy on the basis of multiparametric molecular tumour profiling”. A very complicated sounding title that actually involves work in the field of high-precision radiotherapy aimed at making radiotherapy more precise and reducing the side effects without compromising the effectiveness of radiation treatment. Thorwarth seeks to replace the current notion of anatomy-based dosage with a biologically individualised approach to radiation treatment – in terms of tailoring treatment of head and neck tumours to individual patients, tumours and tissues.
Radiotherapy – alone or in combination with surgery and chemotherapy – plays an important role in the treatment of cancer patients. However, despite modern treatment strategies, advanced tumours in the region of the head and neck can only be cured in around fifty percent of cases. This is partly due to a lack of oxygen in the tumours and other biological resistance mechanisms.
In addition, current treatment and radiation dose determination is based on the anatomical characterisation of the head and neck tumours. Computed tomography is used to determine the size of the tumour and a biopsy for determining the tumour type. The researchers in Dr. Thorwarth’s team do not consider this to be sufficient and have set out to examine biological and genetic factors affecting a tumour’s response to radiation treatment, combined with functional imaging.
The researchers in Thorwarth’s team have long been focussing on the development of new technological aspects and techniques to improve the treatment of cancer patients. They have developed more precise radiation sources and computer algorithms that enable the radiation dose to be determined according to a patient’s specific requirements.
The ERC Starting Grant has now enabled the team to expand the project by numerous parameters; they can integrate other imaging methods into the current technology pool and focus on the biological and genetic properties that affect a tumour’s response to treatment. “We are still developing suitable experiments, but we hope to commence large-scale investigations in 2014,” Thorwarth said. “We want to include numerous new parameters and identify the functional, radiobiological characteristics of cancer cells in order to develop suitable methods for the individualised irradiation of tumours,” the scientist explained. “This knowledge would allow us to specifically treat any tumour.” The examinations of the biological and genetic factors affecting a tumour’s response to radiation treatment are combined with functional imaging in the form of positron emission tomography (PET) and functional magnetic resonance imaging (fMRI). The research project will also involve statistics methods for analysing the large amount of data collected in the project. This is one of the first studies in the world that combines biological and genetic factors with functional imaging in a single model.
In contrast to their previous studies, for their new study Thorwarth and her team will use small-animal models with implanted tumours rather than patient data. A distinctive feature of the new study is the combination of many different parameters in a single mathematical model allowing treatment to be individually tailored to the patient – both locally and biologically.
The scientists expect the first concrete results to be available in about five years’ time. “Although individualised radiotherapy will not yet be standard treatment at that point, we still hope to be able to spend the last two years of the five-year project on a study involving a small patient cohort in order to prove the clinical applicability of the method,” Thorwarth says. “Of course we do not yet know whether we will be able to achieve a paradigm change in radiotherapy by replacing the current notion of anatomy-based dosage with a biologically individualised approach to radiation treatment. But whatever happens, we will be able to make new statements on functional imaging, tumour biology and their suitability for treating head and neck tumours,” Thorwarth says.
Further information:Dr. Daniela ThorwarthUniversity Hospital of Tübingen Department of RadiooncologyBiomedical PhysicsHoppe-Seyler-Str. 372076 TübingenTel.: +49 (0)7071 29-86055E-mail: Daniela.Thorwarth(at)med.uni-tuebingen.de